AAPL   322.47 (+1.37%)
MSFT   183.49 (+0.92%)
FB   229.30 (+0.07%)
GOOGL   1,433.10 (+0.90%)
AMZN   2,424.56 (+0.59%)
NVDA   345.68 (+1.37%)
BABA   202.17 (+0.49%)
MU   47.59 (-3.76%)
GE   6.88 (-5.62%)
TSLA   817.49 (-0.33%)
T   31.43 (-1.35%)
ACB   15.71 (+2.68%)
GILD   75.65 (+1.00%)
NFLX   418.34 (-0.37%)
BAC   25.24 (-2.85%)
BA   151.83 (+1.54%)
AAPL   322.47 (+1.37%)
MSFT   183.49 (+0.92%)
FB   229.30 (+0.07%)
GOOGL   1,433.10 (+0.90%)
AMZN   2,424.56 (+0.59%)
NVDA   345.68 (+1.37%)
BABA   202.17 (+0.49%)
MU   47.59 (-3.76%)
GE   6.88 (-5.62%)
TSLA   817.49 (-0.33%)
T   31.43 (-1.35%)
ACB   15.71 (+2.68%)
GILD   75.65 (+1.00%)
NFLX   418.34 (-0.37%)
BAC   25.24 (-2.85%)
BA   151.83 (+1.54%)
AAPL   322.47 (+1.37%)
MSFT   183.49 (+0.92%)
FB   229.30 (+0.07%)
GOOGL   1,433.10 (+0.90%)
AMZN   2,424.56 (+0.59%)
NVDA   345.68 (+1.37%)
BABA   202.17 (+0.49%)
MU   47.59 (-3.76%)
GE   6.88 (-5.62%)
TSLA   817.49 (-0.33%)
T   31.43 (-1.35%)
ACB   15.71 (+2.68%)
GILD   75.65 (+1.00%)
NFLX   418.34 (-0.37%)
BAC   25.24 (-2.85%)
BA   151.83 (+1.54%)
AAPL   322.47 (+1.37%)
MSFT   183.49 (+0.92%)
FB   229.30 (+0.07%)
GOOGL   1,433.10 (+0.90%)
AMZN   2,424.56 (+0.59%)
NVDA   345.68 (+1.37%)
BABA   202.17 (+0.49%)
MU   47.59 (-3.76%)
GE   6.88 (-5.62%)
TSLA   817.49 (-0.33%)
T   31.43 (-1.35%)
ACB   15.71 (+2.68%)
GILD   75.65 (+1.00%)
NFLX   418.34 (-0.37%)
BAC   25.24 (-2.85%)
BA   151.83 (+1.54%)
Log in

NYSE:MDMEDNAX Stock Price, Forecast & News

$16.32
-0.31 (-1.86 %)
(As of 05/28/2020 02:42 PM ET)
Add
Compare
Today's Range
$16.31
Now: $16.32
$17.00
50-Day Range
$10.88
MA: $13.49
$15.50
52-Week Range
$7.37
Now: $16.32
$28.66
Volume51,450 shs
Average Volume1.35 million shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.4
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and their unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of December 31, 2018, it had a network of approximately 4,210 affiliated physicians. The company was founded in 1979 and is based in Sunrise, Florida.
Read More
MEDNAX logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.91 out of 5 stars


Industry, Sector and Symbol

Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
CUSIP58502B10
Phone954-384-0175

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.51 billion
Cash Flow$22.05 per share
Book Value$17.42 per share

Profitability

Net Income$-1,497,700,000.00

Miscellaneous

Employees5,165
Market Cap$1.39 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.

MEDNAX (NYSE:MD) Frequently Asked Questions

How has MEDNAX's stock been impacted by COVID-19 (Coronavirus)?

MEDNAX's stock was trading at $13.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MD stock has increased by 16.7% and is now trading at $16.32. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MEDNAX?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 8 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for MEDNAX.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for MEDNAX.

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) released its quarterly earnings data on Thursday, May, 7th. The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.52 by $0.20. The firm earned $846 million during the quarter, compared to analyst estimates of $850.88 million. MEDNAX had a positive return on equity of 12.72% and a negative net margin of 36.30%. The firm's revenue was down .6% on a year-over-year basis. During the same quarter last year, the company earned $0.71 earnings per share. View MEDNAX's earnings history.

What price target have analysts set for MD?

12 brokers have issued 12-month price targets for MEDNAX's stock. Their forecasts range from $11.00 to $33.00. On average, they anticipate MEDNAX's share price to reach $19.67 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price. View analysts' price targets for MEDNAX.

Has MEDNAX been receiving favorable news coverage?

News headlines about MD stock have been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MEDNAX earned a news impact score of -3.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutMEDNAX.

Who are some of MEDNAX's key competitors?

What other stocks do shareholders of MEDNAX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Gilead Sciences (GILD), Pfizer (PFE), Dominion Energy (D), Walt Disney (DIS), Carnival (CCL), Chevron (CVX), Delta Air Lines (DAL), NVIDIA (NVDA), Exxon Mobil (XOM) and AbbVie (ABBV).

Who are MEDNAX's key executives?

MEDNAX's management team includes the following people:
  • Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 72)
  • Mr. Joseph M. Calabro, Pres (Age 58)
  • Mr. Stephen D. Farber, Exec. VP & CFO (Age 49)
  • Mr. David A. Clark, Chief Operating Officer (Age 52)
  • Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 50)

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

Who are MEDNAX's major shareholders?

MEDNAX's stock is owned by a number of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (9.74%), Starboard Value LP (9.24%), BlackRock Inc. (9.14%), State Street Corp (2.88%), Bank of New York Mellon Corp (1.50%) and Aristotle Capital Boston LLC (1.25%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View institutional ownership trends for MEDNAX.

Which major investors are selling MEDNAX stock?

MD stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Two Sigma Investments LP, BNP Paribas Arbitrage SA, Mackay Shields LLC, Principal Financial Group Inc., Ensign Peak Advisors Inc, Schroder Investment Management Group, and BlackRock Inc.. View insider buying and selling activity for MEDNAX.

Which major investors are buying MEDNAX stock?

MD stock was bought by a variety of institutional investors in the last quarter, including Starboard Value LP, ArrowMark Colorado Holdings LLC, Silver Rock Financial LP, State Street Corp, William Blair Investment Management LLC, Two Sigma Advisers LP, Canada Pension Plan Investment Board, and Robeco Institutional Asset Management B.V.. View insider buying and selling activity for MEDNAX.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $16.32.

How big of a company is MEDNAX?

MEDNAX has a market capitalization of $1.39 billion and generates $3.51 billion in revenue each year. The company earns $-1,497,700,000.00 in net income (profit) each year or $3.14 on an earnings per share basis. MEDNAX employs 5,165 workers across the globe.

What is MEDNAX's official website?

The official website for MEDNAX is www.mednax.com.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.